Celsis acquires In Vitro Technologies for $30M
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Celsis |
In Vitro Tech |
$30M acquisition |
Celsis has acquired In Vitro Technologies for $30 million in cash and an earn-out consideration capped at $5 million. |
|
Biogen Idec |
Amorfix Life Sciences |
$25.4M licensing deal |
Biogen Idec has the option to use Amorfix's technology to develop and commercialize therapeutic products directed against Amyotrophic Lateral Sclerosis. |
|
Bio-Rad Laboratories |
Ciphergen Biosystems |
$20M acquisition |
Bio-Rad will acquire Ciphergen Biosystems' proteomics instrument business. |
|
Meda |
BioDelivery Sciences International's |
$2.5M |
Meda has acquired the European development and commercialization rights to BioDelivery Sciences International's BEMA Fentanyl. |
|
Genentech |
Genizon BioSciences |
Licensing deal |
Genentech gains licensing rights to Genizon's GeneMap of disease-associated genes generated from a whole genome association study of Crohn's disease patients from the Quebec Founder Population. |
|
BrainCells |
Mitsubishi Pharma |
Licensing deal |
BrainCells has in-licensed a clinical-stage compound from Mitsubishi Pharma that BCI will reposition and develop for the treatment of central nervous system diseases, including mood disorders. |